Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 16, 2023 - Issue
Submit an article Journal homepage
299
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization

Jonathan Corren1 David Geffen School of Medicine at UCLA, Los Angeles, CA, USACorrespondence[email protected]
,
David J Jackson2 King’s College London, London, UK;3 Guy’s and St Thomas’ NHS Foundation Trust, London, UK
,
Thomas B Casale4 Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA
,
Larry Borish5 Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, VA, USA;6 Carter Immunology Center, University of Virginia Health System, Charlottesville, VA, USA
,
Klaus F Rabe7 LungenClinic Grosshansdorf (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany;8 Christian-Albrechts University (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, GermanyORCID Iconhttps://orcid.org/0000-0002-7020-1401
ORCID Icon,
William W Busse9 UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USAORCID Iconhttps://orcid.org/0000-0003-2591-4696
ORCID Icon,
Jorge F Maspero10 Fundación CIDEA, Buenos Aires, Argentina
,
Daniel J Jackson11 University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
,
Nadia Daizadeh12 Sanofi, Cambridge, MA, USA
,
Arman Altincatal12 Sanofi, Cambridge, MA, USA
,
Amr Radwan13 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
,
Angela Khodzhayev13 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
,
Michel Djandji12 Sanofi, Cambridge, MA, USA
,
Juby A Jacob-Nara12 Sanofi, Cambridge, MA, USA;14 Sanofi, Bridgewater, NJ, USA
,
Paul J Rowe14 Sanofi, Bridgewater, NJ, USA
&
Yamo Deniz13 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
 show all
Pages 249-260 | Received 09 Aug 2022, Accepted 30 Jan 2023, Published online: 07 Mar 2023

References

  • Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–233. doi:10.1007/s12016-018-8712-1
  • Hall S, Agrawal DK. Key mediators in the immunopathogenesis of allergic asthma. Int Immunopharmacol. 2014;23(1):316–329. doi:10.1016/j.intimp.2014.05.034
  • Godar M, Blanchetot C, de Haard H, Lambrecht BN, Brusselle G. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs. 2018;10(1):34–45. doi:10.1080/19420862.2017.1392425
  • Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014;111(14):5147–5152. doi:10.1073/pnas.1323896111
  • Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111(14):5153–5158. doi:10.1073/pnas.1324022111
  • Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi:10.1080/1744666X.2017.1298443
  • Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. doi:10.1111/all.14151
  • Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092
  • Corren J, Castro M, O’Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516–526. doi:10.1016/j.jaip.2019.08.050
  • Carr W, Jackson DJ, Corren J, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma by immunoglobin E levels at baseline. Eur Respir J. 2019;54(suppl 63):PA536.
  • Busse WW, Maspero JF, Rabe KF, et al. Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther. 2018;35(5):737–748. doi:10.1007/s12325-018-0702-4
  • Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99. doi:10.1164/rccm.200801-060ST
  • Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–907. doi:10.1034/j.1399-3003.1999.14d29.x
  • Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. doi:10.1016/S0140-6736(16)30307-5
  • Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa1804093
  • Busse WW, Maspero JF, Lu Y, et al. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020;125(5):565–576.e1. doi:10.1016/j.anai.2020.05.026
  • Soong W, Yoo B, Pazwash H, Holweg CTJ, Casale TB. Omalizumab response in patients with asthma by number and type of allergen. Ann Allergy Asthma Immunol. 2021;127(2):223–231. doi:10.1016/j.anai.2021.04.002
  • Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504–511.e4. doi:10.1016/j.anai.2018.01.030
  • Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J. 2014;44(1):239–241. doi:10.1183/09031936.00220413
  • Pelaia C, Crimi C, Pelaia G, et al. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allergy. 2020;50(7):780–788. doi:10.1111/cea.13613

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.